These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11152017)

  • 1. Lopinavir.
    Hurst M; Faulds D
    Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Oldfield V; Plosker GL
    Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
    Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
    Calza L; Mosca L; Pocaterra D; Piergentili B; Colangeli V; Manfredi R; Erario A; Grossi G; Verucchi G; Viale P
    Eur J Clin Pharmacol; 2011 Feb; 67(2):143-9. PubMed ID: 20878151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
    Podzamczer D; King MS; Klein CE; Flexner C; Katlama C; Havlir DV; Letendre SL; Eron JJ; Brun SC; Bernstein B
    HIV Clin Trials; 2007; 8(4):193-204. PubMed ID: 17720659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.
    Kaplan SS; Hicks CB
    Expert Opin Pharmacother; 2005 Aug; 6(9):1573-85. PubMed ID: 16086645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
    Barragan P; Podzamczer D
    Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    Chadwick EG; Capparelli EV; Yogev R; Pinto JA; Robbins B; Rodman JH; Chen J; Palumbo P; Serchuck L; Smith E; Hughes M;
    AIDS; 2008 Jan; 22(2):249-55. PubMed ID: 18097227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.